Abstract
Fatty acid synthase (FAS) is a key enzyme of the fatty acid biosynthetic pathway which catalyzes de novo lipid synthesis. FAS expression in normal adult tissues is generally very low or undetectable as majority of fatty acids obtained are from dietary sources, whereas it is significantly upregulated in cancer cells despite adequate nutritional lipid supply. Activation of FAS provides rapidly proliferating tumor cells sufficient amount of lipids for membrane biogenesis and confers growth and survival advantage possibly acting as a metabolic oncogene. Importantly, inhibition of FAS in cancer cells using the pharmacological FAS inhibitors results in tumor cell death by apoptosis whereas normal cells are resistant. Due to this differential expression of FAS, the inhibitors of this enzyme are selectively toxic to tumor cells and therefore FAS is considered an attractive therapeutic target for cancer. Several FAS inhibitors are already patented and commercially available; however, the potential toxicity of these FAS inhibitors remains to be tested in clinical trials. In this review, we discuss some of the potent FAS inhibitors along with their patent information, the mechanism of anti-cancer effects and the development of more specific and potent FAS inhibitors with lower side effects that are expected to emerge as anti-cancer treatment in the near future.
Keywords: Apoptosis, fatty acid synthase, FAS inhibitors, lipogenesis, patents
Recent Patents on Anti-Cancer Drug Discovery
Title:Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS)
Volume: 7 Issue: 2
Author(s): Puspa R. Pandey, Wen Liu, Fei Xing, Koji Fukuda and Kounosuke Watabe
Affiliation:
Keywords: Apoptosis, fatty acid synthase, FAS inhibitors, lipogenesis, patents
Abstract: Fatty acid synthase (FAS) is a key enzyme of the fatty acid biosynthetic pathway which catalyzes de novo lipid synthesis. FAS expression in normal adult tissues is generally very low or undetectable as majority of fatty acids obtained are from dietary sources, whereas it is significantly upregulated in cancer cells despite adequate nutritional lipid supply. Activation of FAS provides rapidly proliferating tumor cells sufficient amount of lipids for membrane biogenesis and confers growth and survival advantage possibly acting as a metabolic oncogene. Importantly, inhibition of FAS in cancer cells using the pharmacological FAS inhibitors results in tumor cell death by apoptosis whereas normal cells are resistant. Due to this differential expression of FAS, the inhibitors of this enzyme are selectively toxic to tumor cells and therefore FAS is considered an attractive therapeutic target for cancer. Several FAS inhibitors are already patented and commercially available; however, the potential toxicity of these FAS inhibitors remains to be tested in clinical trials. In this review, we discuss some of the potent FAS inhibitors along with their patent information, the mechanism of anti-cancer effects and the development of more specific and potent FAS inhibitors with lower side effects that are expected to emerge as anti-cancer treatment in the near future.
Export Options
About this article
Cite this article as:
R. Pandey Puspa, Liu Wen, Xing Fei, Fukuda Koji and Watabe Kounosuke, Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS), Recent Patents on Anti-Cancer Drug Discovery 2012; 7 (2) . https://dx.doi.org/10.2174/157489212799972891
DOI https://dx.doi.org/10.2174/157489212799972891 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Triggering Receptor Expressed on Myeloid Cells (TREM) Family and the Application of Its Antagonists
Recent Patents on Anti-Infective Drug Discovery Histamine-Dependent and -Independent Hypersensitivity Reactions to Contrast Media: The Impact of Antihistamines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Intracardiac Origin of Heart Rate Variability, Pacemaker Funny Current and their Possible Association with Critical Illness
Current Cardiology Reviews Sleep-Related Disorders, Diabetes and Obesity: Understanding the Facts
Current Respiratory Medicine Reviews Enhanced Selectivity Screening of GPCR Ligands Using a Label-Free Cell Based Assay Technology
Combinatorial Chemistry & High Throughput Screening Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well?
Current Cardiology Reviews Estrogen Receptor Polymorphisms: Significance to Human Physiology, Disease and Therapy
Recent Patents on DNA & Gene Sequences Is Hyperhomocyst(e)inemia A Humoral Predictor of Coronary Heart Disease?
Current Pharmaceutical Design Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Allograft-Induced Proliferation of Vascular Smooth Muscle Cells: Potential Targets for Treating Transplant Vasculopathy
Current Vascular Pharmacology Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Current Cancer Drug Targets The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Chemical Composition and Biological Effects of Essential Oils from Some Aromatic and Medicinal Plants
The Natural Products Journal HDL as a Target for Glycemic Control
Current Drug Targets Antioxidant to Treat Osteoarthritis: Dream or Reality?
Current Drug Targets Mass Spectrometry-Based Metabolic Profiling
Current Metabolomics Neurotrophins' Modulation by Olive Polyphenols
Current Medicinal Chemistry Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment
Current Vascular Pharmacology Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry